
iBio IBIO
€ 1.00
0.89%
Land |
|
IPO-Jahr |
- |
Branche |
Pharmaeinzelhändler |
Börse |
NYSE AMERICAN |
Anteile |
104 M |
Marktkapitalisierung |
$ 117 M |
EBITDA (LTM) |
$ -32.4 M |
P/E (LTM) |
-3.742857 |
P/S (LTM) |
1363.186 |
EPS (LTM) |
-0.35 |
Andere Aktien der Branche "Pharmaeinzelhändler"
| Name | Preis | % 24h | Marktkapitalisierung | Börse | Land | |
|---|---|---|---|---|---|---|
|
IVERIC bio
ISEE
|
- | - | $ 5.51 B | Nasdaq Global Select Market | ||
|
Myovant Sciences Ltd.
MYOV
|
- | -0.04 % | $ 2.62 B | NYSE | ||
|
Virpax Pharmaceuticals
VRPX
|
- | -45.12 % | $ 2.85 M | Nasdaq Global Select Market | ||
|
Metacrine
MTCR
|
- | - | $ 24.2 M | Nasdaq Global Select Market | ||
|
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | ||
|
Molecular Templates
MTEM
|
- | -23.43 % | $ 495 K | Nasdaq Capital Market | ||
|
CohBar
CWBR
|
- | -15.44 % | $ 2.2 M | Nasdaq Capital Market | ||
|
Deciphera Pharmaceuticals
DCPH
|
- | - | $ 2.18 B | Nasdaq Global Select Market,SPB | ||
|
Entasis Therapeutics Holdings
ETTX
|
- | - | $ 105 M | Nasdaq Global Market | ||
|
Global Blood Therapeutics
GBT
|
- | - | $ 4.62 B | Nasdaq Global Select Market,SPB | ||
|
Idera Pharmaceuticals
IDRA
|
- | -23.04 % | $ 26.6 M | Nasdaq Global Select Market | ||
|
ImmunoGen
IMGN
|
- | - | $ 7.92 B | Nasdaq Global Select Market | ||
|
Infinity Pharmaceuticals
INFI
|
- | -46.98 % | $ 3.57 M | Nasdaq Global Select Market | ||
|
Novan
NOVN
|
- | -24.84 % | $ 2.64 M | Nasdaq Capital Market | ||
|
NanoString Technologies
NSTG
|
- | -37.43 % | $ 5.1 M | Nasdaq Global Select Market | ||
|
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | ||
|
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | ||
|
AVEO Pharmaceuticals
AVEO
|
- | - | $ 521 M | Nasdaq Capital Market | ||
|
Inozyme Pharma
INZY
|
- | - | $ 207 M | Nasdaq Global Select Market | ||
|
Sorrento Therapeutics
SRNE
|
- | -29.58 % | $ 126 M | Nasdaq Global Select Market | ||
|
Surface Oncology
SURF
|
- | - | $ 59.7 M | Nasdaq Global Select Market | ||
|
Orgenesis
ORGS
|
- | -33.86 % | $ 61.2 M | Nasdaq Capital Market | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 12.97 | 0.78 % | $ 839 M | NYSE | ||
|
Inhibrx
INBX
|
$ 94.56 | 0.92 % | $ 4.46 B | Nasdaq Global Select Market | ||
|
RedHill Biopharma Ltd.
RDHL
|
$ 0.49 | 1.0 % | $ 6.04 B | Nasdaq Global Market | ||
|
Tiziana Life Sciences PLC
TLSA
|
$ 1.07 | 0.45 % | $ 114 M | Nasdaq Global Market | ||
|
XTL Biopharmaceuticals Ltd.
XTLB
|
$ 2.18 | 0.93 % | $ 1.47 B | Nasdaq Capital Market | ||
|
Zymeworks
ZYME
|
$ 26.21 | 4.21 % | $ 1.35 B | NYSE | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
Cidara Therapeutics
CDTX
|
- | - | $ 1.41 B | Nasdaq Global Market | ||
|
Corner Growth Acquisition Corp.
COOL
|
- | -0.89 % | $ 114 M | Nasdaq Global Select Market | ||
|
Dynavax Technologies Corporation
DVAX
|
- | - | $ 2.02 B | Nasdaq Capital Market | ||
|
Iterum Therapeutics
ITRM
|
- | - | $ 591 K | Nasdaq Global Select Market | ||
|
Mersana Therapeutics
MRSN
|
- | - | $ 3.56 B | Nasdaq Global Select Market | ||
|
Humanigen
HGEN
|
- | -81.12 % | $ 4.28 M | Nasdaq Global Select Market | ||
|
Morphic Holding
MORF
|
- | - | $ 2.42 B | Nasdaq Global Market | ||
|
Jounce Therapeutics
JNCE
|
- | - | $ 98.4 M | Nasdaq Global Select Market | ||
|
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | ||
|
Verona Pharma plc
VRNA
|
- | - | $ 69.7 B | Nasdaq Global Select Market | ||
|
Clovis Oncology
CLVS
|
- | -7.23 % | $ 13 M | Nasdaq Global Select Market | ||
|
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | ||
|
Concert Pharmaceuticals
CNCE
|
- | - | $ 401 M | Nasdaq Global Market | ||
|
Evelo Biosciences
EVLO
|
- | -14.46 % | $ 27.9 M | Nasdaq Global Select Market | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
- | - | $ 384 M | Nasdaq Global Select Market | ||
|
Genocea Biosciences
GNCA
|
- | -15.0 % | $ 3.04 M | Nasdaq Global Select Market | ||
|
Amryt Pharma plc
AMYT
|
- | - | $ 621 M | Nasdaq Global Select Market | ||
|
G1 Therapeutics
GTHX
|
- | - | $ 370 M | Nasdaq Global Select Market,SPB |